RedHill Biopharma (RDHL) Further Analysis of Phase 2/3 Data Shows 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients

Go back to RedHill Biopharma (RDHL) Further Analysis of Phase 2/3 Data Shows 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients
REDHILL BIO SP ADS (NASDAQ: RDHL) Delayed: 0.96 --0 (-0%)
Previous Close $0.96    52 Week High $16.54 
Open $0.98    52 Week Low $8.10 
Day High $1.04    P/E N/A 
Day Low $0.96    EPS $0.00 
Volume 477,502